Insulin Icodec Bests Degludec; FDA's T2D Device Guidance; Farxiga Cuts HF Risks | MedPage Today
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec (NVO) | Seeking Alpha
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19 - MidgardFinance.com
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes - Philis‐Tsimikas - Diabetes, Obesity and Metabolism - Wiley Online Library
Insulin "Icodec" Could Be a Diabetes Breakthrough with a Half Life of Over 8 Days - The Diabetes Site News
Novo Nordisk Once-weekly Insulin Icodec Shows Comparable Efficacy To Once-daily Insulin Glargine U100 in Phase 2 trial
Novo Nordisk once-weekly insulin icodec beats Tresiba, matches Sanofi's Lantus in trials | Seeking Alpha
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
Novo Nordisk achieve headline results with icodec insulin | pharmaphorum
Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin — MedWatch
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Novo afslutter sidste af seks succesfulde studier med ugentlig insulin - Dagens Medicin
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Novo Nordisk's once-weekly insulin hits goals in phase 3 trials
Novo Nordisk to file for regulatory approval of once-weekly insulin icodec next year
